☆ 4.7 Article

Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal Antibodies

CLINICAL INFECTIOUS DISEASES (2022)

Related references

Note: Only part of the references are listed.

Letter Rheumatology

Correspondence on 'Systemic sclerosis and the COVID-19 pandemic-World Scleroderma Foundation preliminary advice for patient management'

Elena Snarskaya et al.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Immunology

Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?

Chanu Rhee et al.

Summary: SARS-CoV-2 is most contagious around symptom onset, with infectivity rapidly decreasing to near-zero afterwards; mild-moderately ill patients can safely discontinue isolation after about 10 days, while severely-critically ill and immunocompromised patients may need 15 days. The longest duration associated with replication-competent virus is 20 days.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Clinical Neurology

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Maria P. Sormani et al.

Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.

ANNALS OF NEUROLOGY (2021)

Add to Collection

Article Rheumatology

Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

Florence Aeschlimann et al.

Summary: In this French cohort study of RMD COVID-19 patients, older age, male gender, obesity, and hypertension were found to be associated with severe COVID-19, similar to the general population. Patients with iRMD on corticosteroids, but not methotrexate, tumor necrosis factor alpha, and interleukin-6 inhibitors, were more likely to develop severe COVID-19. Unlike common comorbidities, such as obesity, cardiovascular or lung diseases, the risk of death in patients with iRMD was not significantly increased.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Hematology

Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies

Albrecht Betrains et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Editorial Material Infectious Diseases

Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity Comment

Dafna Yahav et al.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Letter Rheumatology

Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab

Marcia A. Friedman et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Oncology

Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy

Marc S. Hoffmann et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Letter Virology

Protracted SARS-CoV-2 pneumonia with rituximab treatment: About two cases

Victor Gerber et al.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Hematology

Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma

Irati Ormazabal Velez et al.

Summary: The use of convalescent plasma therapy in lymphoma patients with low gammaglobulin levels showed effectiveness in treating relapsed COVID-19, leading to clinical improvement and reducing the risk of virus relapse.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Letter Infectious Diseases

Clinical characteristics of 51,815 patients presenting with positive and negative SARS-CoV-2 swab results in primary health care settings: Priority populations for vaccination

Ehab Hamed et al.

JOURNAL OF INFECTION (2021)

Add to Collection

Article Medicine, General & Internal

Major determinants of death in patients hospitalized with COVID-19 during the first epidemic wave in Madrid, Spain

Victor Moreno-Torres et al.

Summary: Spain, particularly Madrid, was heavily impacted by COVID-19, with about 1752 patients admitted with suspected SARS-CoV-2 infection. The median age of hospitalized patients was 65 years, with a 13.8% mortality rate.

MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Cancer and SARS-CoV-2 Infection: A Third-Level Hospital Experience

Virginia Calvo et al.

Summary: The study conducted in hospitals in Madrid showed that the in-hospital mortality rate of cancer patients with COVID-19 was 15.2%, higher than that of patients without SARS-CoV-2 infection. Patients with lung cancer had a higher mortality rate. Risk factors for developing severe complications included higher Brescia index, CURB-65 scale, lactate dehydrogenase (LDH), and C-reactive protein (CRP).

CLINICAL EPIDEMIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry

Maria del Mar Ayala Gutierrez et al.

Summary: The analysis of hospitalized COVID-19 patients with autoimmune diseases (ADs) compared to the general population did not show a significant difference in overall prognosis, but individual diseases may have varying effects. Immunosuppressive/immunoregulatory treatments (IST) prior to admission had variable effects on outcomes.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Article Health Care Sciences & Services

Evolution of a Cohort of COVID-19 Infection Suspects Followed-Up from Primary Health Care

Valle Coronado-Vazquez et al.

Summary: Telephone consultations by primary health care professionals are effective in monitoring the progression of COVID-19 patients and detecting complications early. Factors associated with hospital admission include being male, having hypertension, diabetes, renal insufficiency, or being immunosuppressed.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection

Article Rheumatology

Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?

Cristiana Sieiro Santos et al.

Summary: The study found that patients treated with biological agents have a lower risk of contracting COVID-19 and can still be managed at home during the outbreak, while IL-6 inhibitors may have a protective effect.

RMD OPEN (2021)

Add to Collection

Letter Infectious Diseases

An interactive web-based dashboard to track COVID-19 in real time

Ensheng Dong et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Article Immunology

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Li Guo et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection

Review Immunology

Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art

Gabriel Siracusano et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Immunology

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

Dennis McGonagle et al.

AUTOIMMUNITY REVIEWS (2020)

Add to Collection

Letter Infectious Diseases

Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?

Marie Gousseff et al.

JOURNAL OF INFECTION (2020)

Add to Collection

Article Hematology

Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19

Thomas Hueso et al.

BLOOD (2020)

Add to Collection

Review Physiology

COVID-19 and the Immune System

Jan Paces et al.

PHYSIOLOGICAL RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry

J. M. Casas-Rojo et al.

REVISTA CLINICA ESPANOLA (2020)

Add to Collection

Article Rheumatology

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study

Jesus Loarce-Martos et al.

RHEUMATOLOGY INTERNATIONAL (2020)

Add to Collection

Letter Rheumatology

Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease

Chia Siang Kow et al.

RHEUMATOLOGY INTERNATIONAL (2020)

Add to Collection

Letter Medicine, General & Internal

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Bina Choi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Letter Rheumatology

B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?

Puja Mehta et al.

LANCET RHEUMATOLOGY (2020)

Add to Collection

Review Immunology

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Rudragouda Channappanavar et al.

SEMINARS IN IMMUNOPATHOLOGY (2017)

Add to Collection

Review Biochemistry & Molecular Biology

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

MR Smith

ONCOGENE (2003)

Add to Collection

Article Oncology

Mechanism of action of rituximab

T Cerny et al.

ANTI-CANCER DRUGS (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.